Cotazym Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to clinical acceptance of enzyme replacement therapies, rising cystic fibrosis prevalence, increased awareness of pancreatic disorders, hospital driven digestive disorder management, improved diagnostic capabilities.

The growth in the forecast period can be attributed to growth in chronic pancreatitis cases, expanding geriatric population, improved access to digestive care therapies, rising focus on nutrition optimization, expansion of specialty gastroenterology clinics. Major trends in the forecast period include rising demand for pancreatic enzyme replacement therapy, growing diagnosis of pancreatic insufficiency disorders, increased focus on digestive health management, expansion of long term enzyme supplementation use, improved formulations for better nutrient absorption.

The rising prevalence of gastrointestinal diseases is expected to drive the growth of the Cotazym market in the coming years. Gastrointestinal diseases encompass a wide range of conditions affecting the digestive system, including the stomach, intestines, liver, pancreas, and related organs. This increase is largely due to poor dietary habits, such as high consumption of processed foods, and rising obesity rates, both of which contribute to the development of digestive disorders. Cotazyme, a digestive enzyme supplement, supports patients with gastrointestinal diseases by improving nutrient absorption and alleviating digestive discomfort through targeted support for enzyme deficiencies, thereby enhancing overall gut health and function. For example, in September 2023, the National Institutes of Health (NIH), a US-based government agency, reported that the prevalence of Inflammatory Bowel Disease (IBD) in Canada was estimated at 825 cases per 100,000 people, affecting over 320,000 individuals. This prevalence is projected to increase by 2.44% annually, reaching 1.1% of the population - or 470,000 Canadians - by 2035. Therefore, the growing prevalence of gastrointestinal diseases is driving the Cotazym market.

The increasing prevalence of rare genetic disorders is also expected to propel the growth of the Cotazym market. Genetic disorders are medical conditions caused by abnormalities in an individual’s DNA, including gene mutations or changes in chromosome structure or number. This rising prevalence is fueled by advancements in diagnostic technologies that allow better detection and by increased awareness, leading to higher reporting rates. Cotazyme assists patients with rare genetic disorders, such as cystic fibrosis, by providing essential pancreatic enzymes that aid digestion and nutrient absorption, addressing malabsorption issues caused by exocrine pancreatic insufficiency commonly associated with these conditions. For instance, in October 2024, the Cystic Fibrosis Trust, a UK-based national charity, reported that 11,148 people were living with cystic fibrosis (CF) in the UK in 2022, increasing to 11,318 in 2023. As a result, the rising prevalence of rare genetic disorders is expected to drive the Cotazym market.

The growing demand for biological products is anticipated to further support the expansion of the Cotazym market. Biological products are complex pharmaceutical substances derived from living organisms, used to diagnose, prevent, treat, and cure medical conditions. This increasing demand is driven by environmental concerns, heightened consumer awareness, and the need for sustainable and effective alternatives to synthetic chemicals. Cotazyme contributes to biological product applications by optimizing enzymatic reactions, improving process efficiency, and ensuring higher yields, thereby enhancing overall performance and cost-effectiveness in biotechnological processes. For example, in October 2025, the US Food and Drug Administration (FDA), a federal agency under the Department of Health and Human Services, reported that as of 2024, 76 biosimilars had been approved in the US, representing only a small fraction of all approved biologics. In comparison, over 30,000 generics have been approved, surpassing the total number of approved brand-name drugs. Therefore, the rising demand for biological products is driving the growth of the Cotazym market.

Major companies operating in the cotazym market are Organon & Co.

North America was the largest region in the cotazym market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cotazym market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the cotazym market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have moderately impacted the cotazym market by increasing costs associated with enzyme sourcing, pharmaceutical excipients, and formulation manufacturing. These effects are most noticeable in hospital and specialty pharmacy distribution channels across north america and europe. Higher tariffs have contributed to increased treatment costs for chronic digestive conditions. At the same time, tariffs are encouraging local production of enzyme based therapies. This is supporting long term supply stability for pancreatic enzyme products.

The cotazym market research report is one of a series of new reports that provides cotazym market statistics, including cotazym industry global market size, regional shares, competitors with a cotazym market share, detailed cotazym market segments, market trends and opportunities, and any further data you may need to thrive in the cotazym industry. This cotazym market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Cotazym is a brand of enzyme preparation that generally contains a blend of pancreatic enzymes, mainly amylase, lipase, and protease. These enzymes aid in breaking down carbohydrates, fats, and proteins in the digestive system, supporting digestion and nutrient absorption, especially in individuals with pancreatic insufficiency.

The main product forms of Cotazym are capsules or tablets and powder. Capsules and tablets are common oral medication forms, each designed for specific delivery. Cotazym is distributed through hospital pharmacies, retail pharmacies, and specialty pharmacies, and is used for therapeutic purposes including cystic fibrosis, chronic pancreatitis, and other pancreatic disorders.

The cotazym market consists of sales of products including non-capsulated cotazyme, and cotazyme forte. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.